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the debilitating morbid condition called the dry eye syndrome (DES). The current line of therapy available for dry eye remains sup-
portive and palliative with the patient being dependent on life long and frequent administration of lubricating eye drops. Even
advanced therapies like punctual plugs, cyclosporine B administration, and salivary gland auto-transplantation have led to a limited
success. Under these scenarios, the option of cell based therapy needs to be explored to provide better and long term relief to
these patients. This review gives an overview of the efforts in lacrimal gland regeneration and examines the past and ongoing
research in cell based therapies in animals as well as human lacrimal gland cultures. The authors discuss their first of its kind func-
tionally viable human lacrimal gland in vitro culture system from fresh exenteration specimens. A brief overview of research in near
future and the potential implications of lacrimal gland regenerative therapies have been discussed.
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The human lacrimal gland is an essential component of the
lacrimal functional unit (LFU) which comprises of the lacrimal
gland, the ocular surface (cornea, conjunctiva and the meibo-
mian gland) and the associated sensory and motor nerves
(Figure 1). The LFU controls the secretion of the major com-
ponents of the tear film and is overall responsible for main-
taining the stability of the tear film, transparency of the
cornea and the quality of the image projected onto the
retina.1
Any perturbation in the stability of the tear film leads to
destabilization of the ocular surface which, over a period of
time, can lead to the debilitating morbid condition called
the dry eye syndrome (DES). The composition of the tear film
can be altered due to the dysfunction of either the lacrimalgland or the meibomian glands; however for the purpose
of this review we will restrict our discussion to lacrimal gland
dysfunction. Lacrimal gland dysfunction and destruction is
seen in cases of advancing age, autoimmune disorders, orbi-
tal radiotherapy, low androgen pool etc. This lacrimal dys-
function causes hyperosmolarity of tear film resulting in a
vicious loop of ocular surface inflammation which is responsi-
ble for ocular epithelial damage leading to corneal ulceration
and eventual decline in visual acuity.1
The current line of therapy available for dry eye remains
supportive and palliative with the patient being dependent
on life long, frequent administration of lubricating or
hydrating eye drops. Even advanced therapies like punctal
plugs, cyclosporine B administration, and salivary gland
auto-transplantation have led to a limited success. Under
these scenarios, the option of cell based therapy needse:
al.com
Figure 1. The lacrimal functional unit.
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these patients.Histology, anatomy and physiology
The lacrimal gland is a tubulo-acinar exocrine gland that
consists of secretory columnar epithelium arranged in a
lobular pattern. These secretory acinar cells empty their
secretions into ducts that anastomose into larger excretory
ducts which drain onto the ocular surface. Both the acinar
and the ductal cells have numerous vesicles in their apical
portion while the base is associated with a basement
matrix. Enveloping the secretory acinar cells are myoepi-
thelial cells that contract and squeeze them enabling the
draining of the secretory components into the ducts. Be-
tween the lacrimal lobes are fibroblasts, which produce
the collagen and matrix of interstitial spaces, and mast
cells, which secrete histamine and heparin. In addition to
this basic tissue architecture, the lacrimal gland is highly
inundated with trafficking B and T lymphocytes as well
as plasma cells.2
The lacrimal gland has both the sympathetic as well as
parasympathetic innervation.3 These nerves have a large
number of cholinergic fibers and fewer adrenergic fibers.
The parasympathetic postganglionic neural cell bodies are
found in the pterygopalatine (sphenopalatine) ganglion as
well as the ciliary ganglion. Sympathetic fibers arise in the
superior cervical ganglion. There is also some sensory inner-
vation of the gland from the trigeminal ganglia.4
The lacrimal gland secretes a number of proteins like lyso-
zyme, lactoferrin, lipocalin, and scIgA.5 The secretion of these
proteins is regulated by the nerves and their associated neu-
rotransmitters or neuropeptides.2 The important receptors
present on the lacrimal gland are acetylcholine receptors like
muscarinic M3, vasoactive intestinal peptide types I and II
and norepinephrine receptors like alpha 1 and beta.6 Other
receptors present are for interacting with neuropeptide Y,
adrenocorticotrophic hormone (ACTH) and alpha- melano-
cyte stimulating hormone (MSH). Since the epithelial cellsof the gland are extensively coupled by junctional complexes,
secondary messengers like inositol triphosphate can easily
diffuse between cells and activate the unstimulated cells
too.2
The dry eye syndrome
The International Dry Eye Workshop, 20071 defined dry
eye as:
‘‘Dry eye is a multifactorial disease of the tears and ocular
surface that results in symptoms of discomfort, visual dis-
turbances and tears film instability with potential damage
to the ocular surface. It is accompanied by increased
osmolarity of tear film and inflammation of the ocular
surface.’’Dry eye is associated with a high incidence of ocular
morbidity. The current prevalence of dry eye in the world is
estimated at around 11% to 22%.7 In the Indian context,
these numbers are estimated to be around 18.4–20%.8,9
These epidemiological numbers are a good indicator of the
need for research on dry eye syndrome.
The etiology of DES involves a vicious loop of tear
hyperosmolarity, tear film instability and ocular surface
inflammation.10 In addition to this, there is also loss of
anti-inflammatory environment within the gland which may
happen in cases of low androgen pool. Severe dry eye is
also seen in patients of Sjogren’s syndrome in which auto-
antigens are expressed at the surface of the epithelial cells.
These cause homing and retention of tissue specific CD4
and CD8 cells, leading to immune-mediated destruction of
the acinar and ductal components.
Orbital radiation therapy, which is a commonly used
modality in the treatment of oculo-adenexal disorders includ-
ing malignant tumors, has also been implicated in the devel-
opment of DES in patients. Despite a rapid evolution in the
field of radiotherapy over the past years, a significant number
of patients are still seen with acute and chronic ophthalmic
complications including severe dry eye.11,12 Preliminary data
from our institute indicate that chronic dry eye develops in
over 49% of the patients who undergo external beam radia-
tion therapy for ocular malignancies (unpublished data).
Contact lens wear is yet another condition that may lead
to the development of severe dry eye in long-term users. Re-
duced corneal sensitivity and tear film hyperosmolarity are
the probable underlying mechanisms.1
The current treatment modalities available for DES are
lubricating agents like hydroxymethyl cellulose, solutions
containing bicarbonates and potassium, hyposmotic artificial
tears and artificial serum. In cases of severe dry eye, therapies
such as anti-inflammatory medications (cyclosporin A, corti-
costeroids), pharmacological tear stimulants like diquafosol,
rebamipide, ecabet sodium, pilocarpine etc. have also been
used. In certain severe cases, surgical interventions like punc-
tal occlusion and salivary gland auto-transplantation are done
to slow down the progress of the condition and minimize det-
rimental sequale.13
On recommendation of the committee on the therapy and
management of dry eye, the treatment or management pro-
tocol for this condition is now shifting toward employing
strategies that would increase the natural production of
tears, maintain ocular surface integrity and reduce or elimi-
14 S. Tiwari et al.nate the levels of existing inflammation.13 With these objec-
tives in mind various therapeutic avenues are being explored
with the inclusion of cell therapy for restoring the function of
the damaged lacrimal gland.Lacrimal gland regeneration
Currently available data on the etiopathogenesis and
treatment of dry eye are still insufficient to explain how alter-
ation in tear film composition can cause such a vicious cycle
of tear film instability and chronic ocular inflammation. Even
though a lot of research is being directed toward profiling
the proteins, lipids and other constituents of human tear
yet there is a glaring lack of comparative data between nor-
mal individuals and dry eye patients.Animal lacrimal gland in vitro cultures
An important area of investigation in this field is to find a
common link between tear film osmolarity, tear film break up
response and the resultant inflammatory stress. In order to
facilitate these studies, not just in vivo models but also
in vitro models are being developed that would greatly assist
the investigation into the secretory repertoire of lacrimal
gland epithelia, regulation of secretion and etiopathogenesis
of lacrimal gland involvement in disorders like Sjogren’s
syndrome.
Past two decades have seen evolution in the procedure for
in vitro culturing of lacrimal gland acinar cells. Oliver et al.14
published one of the first reports on in vitro culture of rat lac-
rimal gland acinar cells wherein they described a method for
culturing a dividing population of morphologically differenti-
ated rat lacrimal acinar cells on a three-dimensional, reconsti-
tuted basement membrane gel. The cultured acinar cells
proliferated on the basement matrix and showed the
presence of cytoplasmic secretory granules.14 However, their
culture system could only maintain the epithelial cells for
6–7 days after which fibroblast overgrowth was observed.
Successful in vitro culture of lacrimal acinar cells was first
achieved and published by Meneray and Rismondo in two
separate reports in 1994.15,16 Reports from Hann et al.17
and numerous subsequent authors have emphasized the
importance of media formulation, supplement profile and
extracellular matrix composition for optimal growth and func-
tionality of lacrimal acinar cells.
A major problem faced by all these investigators was that
the lacrimal acinar cells could not be induced to proliferate
significantly in vitro until Schonthal et al.18 in 2000 improvisedFigure 2. Human lacrimal gland in vitro cultuon the media composition by the use of epidermal growth
factor (EGF), dihydrotestosterone (DHT), Matrigel™ and
HepatoStim™ culture medium.18 A number of recent publica-
tions also report the use of polyethersulfone dead-end
tube19, denuded amniotic membrane20 as scaffolds and ro-
tary cell culture system21 for successful in vitro culture of rat
or rabbit lacrimal glands. The effect of androgens and andro-
gen analogs on in vitro culture of lacrimal acinar cells has
helped elucidate the control that the androgens exert on
the synthesis and secretion of secretory component17,22–24
as well as other biochemical parameters related to the lacri-
mal secretion including the basal tear flow rate.25
The culture systems developed for the lacrimal acinar cells
have also been optimized to assess the functionality of these
cells. The currently employed conditions for the in vitro cul-
ture of these secretory cells support the in vivo mimicry of
their secretion pattern as elucidated by the detection of scIg-
A, lactoferrin, lysozyme, lacritin and a number of other tear
proteins in the culture supernatant.
You et al.26 showed that post injection of interleukin into
the mouse lacrimal gland which destroys areas in the gland,
stem-like cells migrate toward the site of injury and heal
the wound. These cells could also be harvested and grown
under in vitro conditions. However, the authors report mini-
mum in vitro growth from uninjured gland. In contrast, the re-
cent study by Shatos et al.27 on rat lacrimal gland and our
own experience with human lacrimal gland tissue28 showed
that stem-like cells are present in the native, uninjured gland
too which can be maintained under appropriate in vitro
conditions.
Human lacrimal gland in vitro cultures – our experience
In-vitro work on human lacrimal gland cultures is scarce,
possibly due to the difficulty in obtaining human tissue for re-
search. To the best of our knowledge and literature search,
there is just one report published by Yoshino et al.29 in
2000, which dealt with establishing human lacrimal cultures
from cadaveric tissue. However, the study was a limited re-
port which only partially explored the secretory potential of
the cells and the various sub-populations present.
Our group has been working with human lacrimal gland
cultures since 2008 and we were the first to report the estab-
lishment of functionally viable human lacrimal gland in vitro
cultures from fresh exenteration specimens.28 Our results
show successful establishment of human lacrimal gland cul-
tures on three matrices: Matrigel™, collagen-1 and denuded
human amniotic membrane. We have extensively character-
ized our culture system using markers for epithelial, myoepi-res: phase contrast microscope images.
Figure 3. FACS analysis of fresh human lacrimal gland cells.
Figure 4. FACS analysis of cultured human lacrimal gland cells.
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Figure 5. Potential cell therapy for aqueous deficient dry eye.
16 S. Tiwari et al.thelial and mesenchymal origin by immunohistochemistry/
immunocytochemistry and flow cytometry. Our established
cultures show the capacity to synthesize and secrete quanti-
fiable levels of major tear proteins like scIgA, lactoferrin
and lysozyme into the culture supernatant. We have success-
fully shown that these lacrimal epithelial cultures can be
maintained in vitro, with intact secretory function, for a mini-
mum period of 21 days. In addition, we also reported that by
day 16–18, these in vitro cultures show the appearance of
‘spherules’ and structures that look like ductal connections
between them (Figure 2). We believe that this indicates their
potential for in vitro gland formation.
Toward the long-term goal of cell therapy in chronic dry
eye condition, we have also looked for the presence of
stem-like cells in the native human lacrimal gland as well as
in the established cultures. From the criteria available, we
have used ABCG2, CD117 positivity and ALDH levels, clone
formation ability, quiescence and label retaining properties
to indicate the presence of stem-like cells.
Using flow cytometry and immunochemistry we have
shown preliminary evidence indicating the presence of
stem-like cells (ABCG2 positive, ALDH high) in the native hu-
man lacrimal gland as well as in our in vitro cultures. In the na-
tive gland around 3.1 ± 0.61% of the cells showed ABCG2
positivity and around 3.8 ± 1.26% showed high levels of
ALDH (Figure 3). In the in vitro cultures, the number of cells
that showed ABCG2 positivity by day 14 is 0.3 ± 0.15%,which decreased slightly to 0.2 ± 0.13% by day 21. Similar
is the case with ALDH. CD117, which is a stem cell marker
in exocrine glands, also showed positivity: at time = 0 about
6.7 ± 2.0% of the cells were CD117 positive. This number re-
duced to 0.2 ± 0.05 by day 14 and 0.2 ± 0.05 by day 21
in vitro (Figure 4)
In order to enrich the number of stem cells in vitro we have
also cultured these cells as free floating ‘lacrispheres’ which
are very similar to salispheres and prostaspheres. These
spheres show a fourfold increase in CD117 positive cells
(0.8%), increased clone forming ability and higher percent-
age of label retaining cells than the adherent cultures (unpub-
lished data).
We believe that these lacrispheres are very similar in their
phenotype as well as cellular architecture to salispheres.
Since the latter is being used as a potential cell therapy for
restoring function in animal model of xerostomia,30 we be-
lieve similar results could be expected from lacrispheres too.Conclusion
Even though we have come a long way in managing the
chronic dry eye patients and improving their quality of life,
yet there are a number of aspects that still need to be looked
at and addressed. One of the principle areas that need fo-
cused attention is to understand the mechanisms behind
Human lacrimal gland regeneration: Perspectives and review 17the development and progression of this condition and to
develop biomarker(s) for this condition. A large, well-defined,
staged and age-matched study would probably be required
for this.
A lot of fundamental science we know of dry eye today has
been by correlating animal data with human scenario. In
order to lend credibility to the accrued knowledge, it is
essential that a comparative study be made between human
and mouse or rabbit tears and ocular surface protein–lipid
profiles. This would enable us to identify the common com-
ponents and pathways involved in various forms of this disor-
der and would also give important clues about the treatment
of this condition.
The last couple of years have seen an increase in the
knowledge about the presence of stem-like cells in the lacri-
mal gland of mice,26 rat27 and humans.28 These studies indi-
cate the inherent potential of the gland to heal itself
following an insult. In contrast, the recent study by Shatos
et al.27 on rat lacrimal gland and our own experience with hu-
man lacrimal gland showed that stem-like cells are present in
the native, uninjured gland too which can be maintained un-
der appropriate in vitro conditions.
Another important area that needs to be explored care-
fully is the potential to use cell therapy in chronic cases of
dry eye. Cell therapy is being used successfully to treat a sim-
ilar condition called xerostomia involving the salivary gland
under preclinical settings.30 Even though there is not enough
work that has been done toward cell therapy in dry eye, yet
its similarity with salivary gland leads us to believe that a sim-
ilar therapeutic approach may prove beneficial to the chronic
patients of dry eye too (Figure 5).
The presence of stem cells in the lacrimal gland is an
important finding that leads us to believe that these cells
can be recruited to salvage the damaged gland. However,
before we take a leap of faith, the viability, homing and
functionality of these cells need to be established by more
extensive in vitro studies and independent animal experimen-
tation. Subsequent use of cell based therapies to rescue and
regenerate diseased lacrimal gland in humans is a promising
prospect.Funding agencies
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